Nivolumab

You have access
Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
GAI YAMASHITA, ISAKU OKAMOTO, TATSUYA ITO, KUNIHIKO TOKASHIKI, TAKURO OKADA and KIYOAKI TSUKAHARA

Anticancer Research August 2023, 43 (8) 3679-3683; DOI: https://doi.org/10.21873/anticanres.16550
You have access
Real-world Data and Economic Evaluation of Nivolumab in Previously Treated Non-small Cell Lung Cancer Greek Patients
HELENA LINARDOU, SOFIA LAMPAKI, GEORGIA-ANGELIKI KOLIOU, ATHANASSIOS VOZIKIS, ANASTASIOS BOUTIS, ADAMANTIA NIKOLAIDI, IOANNIS KONTOGIORGOS, PAVLOS PAPAKOTOULAS, ATHINA CHRISTOPOULOU, DIONYSIOS SPYRATOS, DIMITRIOS BAFALOUKOS, AMANDA PSYRRI, ANASTASIOS GRIVAS, ANNA KOUMARIANOU, KARYOFYLLIS TSIAKITZIS, DAVIDE MAURI, GEORGIOS RIGAKOS, GERASIMOS ARAVANTINOS, PANAGIOTIS PAPANTONIOU, GEORGIOS OIKONOMOPOULOS, ELENA FOUNTZILAS, MARGARITA-IOANNA KOUFAKI, MARIA KAPARELOU, ELIAS LIOLIS, GIANNIS MOUNTZIOS, PARIS KOSMIDIS, GEORGE FOUNTZILAS and EPAMINONDAS SAMANTAS

Anticancer Research June 2023, 43 (6) 2799-2812; DOI: https://doi.org/10.21873/anticanres.16449
You have access
Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer
KEI HAYASHI, MITSUHIRO FURUTA, KYOKO FURUSAWA, TOMOMI HAMAGUCHI, MAMORU WATANABE, YASUHIRO INOKUCHI, SHIZUNE ONUMA, ITARU HASHIMOTO, HIDEAKI SUEMATSU, SHINSUKE NAGASAWA, KYOHEI KANEMATSU, TAKANOBU YAMADA, AKIFUMI NOTSU, TAKASHI OGATA, TAKASHI OSHIMA, NOZOMU MACHIDA, JUNJI FURUSE and SHIN MAEDA

Anticancer Research June 2023, 43 (6) 2831-2840; DOI: https://doi.org/10.21873/anticanres.16452
Open Access
A Phase I/II Investigation of Safety and Efficacy of Nivolumab and nab-Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway
ERLINDA M. GORDON, NICOLE L. ANGEL, NADEZHDA OMELCHENKO, VICTORIA S. CHUA-ALCALA, ANIA MORADKHANI, DORIS QUON and STEVEN WONG

Anticancer Research May 2023, 43 (5) 1993-2002; DOI: https://doi.org/10.21873/anticanres.16360
You have access
Real-world Data Study of the Efficacy and Toxicity of Nivolumab vs. Cetuximab and Predictors of Response to Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck in a European Population
LOLA MACIA-RIVAS, CLARA LUZ FERNANDEZ-LAGUNA, CRISTINA ALVAREZ-ASTEINZA, IVAN MARAY, MONICA CARBAJALES-ALVAREZ and ANA LOZANO-BLAZQUEZ

Anticancer Research April 2023, 43 (4) 1681-1688; DOI: https://doi.org/10.21873/anticanres.16320
You have access
Prognostic Value of Serum Soluble PD-L1 in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab
NAOTO WAKITA, NOBUYUKI HINATA, YUKARI BANDO, TAKUTO HARA, TOMOAKI TERAKAWA, JUNYA FURUKAWA, YUZO NAKANO and MASATO FUJISAWA

Anticancer Research February 2023, 43 (2) 841-847; DOI: https://doi.org/10.21873/anticanres.16226
You have access
Examining the Efficacy of Nivolumab for Gastric Cancer Focusing on Using an Inflammation-based Prognostic Score: A Multicenter Retrospective Study
NOBUHIRO NAKAZAWA, MAKOTO SOHDA, KOHEI TATENO, TAKAYOSHI WATANABE, AKIHARU KIMURA, NORIMICHI KOGURE, HISASHI HOSAKA, ATSUSHI NAGANUMA, MASANORI SEKIGUCHI, KANA SAITO, KYOICHI OGATA, AKIHIKO SANO, MAKOTO SAKAI, HIROOMI OGAWA, KEN SHIRABE and HIROSHI SAEKI

Anticancer Research February 2023, 43 (2) 927-934; DOI: https://doi.org/10.21873/anticanres.16236
You have access
Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
TAKURO OKADA, TAKASHI MATSUKI, CHIHIRO FUSHIMI, ISAKU OKAMOTO, HIROKI SATO, TAKAHITO KONDO, KUNIHIKO TOKASHIKI, TATSUYA ITO, TATSUO MASUBUCHI, YUICHIRO TADA, KOUKI MIURA, KENJI HANYU, GO OMURA, HIDEKI TAKAHASHI, TAKU YAMASHITA, NOBUHIKO ORIDATE and KIYOAKI TSUKAHARA

Anticancer Research October 2022, 42 (10) 4907-4912; DOI: https://doi.org/10.21873/anticanres.15996
You have access
The Effect and Tolerability of Second-line Chemotherapy Are Associated With Disease Control by Nivolumab Chemotherapy in Patients With Gastric Cancer
HIROSHI MATSUOKA, TOMOHIRO MIZUNO, MINAMI SAKAI, KAZUMITSU SUZUKI, AKIKO SERIZAWA, MASAYA NAKAUCHI, TSUYOSHI TANAKA, SUSUMU SHIBASAKI, TAKAHIRO HAYASHI and KOICHI SUDA

Anticancer Research October 2022, 42 (10) 4973-4980; DOI: https://doi.org/10.21873/anticanres.16004
You have access
Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?
MARTIN SVATON, MONIKA BRATOVA, LEONA KOUBKOVA, ONDREJ FISCHER, BOHUSLAV MELICHAR, MICHAL HRNCIARIK, DANIEL DOLEZAL, ONDREJ BILEK, JANA KREJCI, MARIE DROSSLEROVA, ZDENKA DLOUHA, JIRI BLAZEK, PETRA MAJKOVA, LUCIE BROZOVA and MAREK STASTNY

Anticancer Research April 2022, 42 (4) 1987-1995; DOI: https://doi.org/10.21873/anticanres.15677

Main menu

User menu

Search

Nivolumab

Pages